Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 2/20 | 0.73 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 4/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2560139 | 0.87 | LIPE (0.63) | LIPEENPP2MAPTMAPK1TDP1 | |
| SCHEMBL29591898 | 0.84 | LIPE (1.00) | LIPEENPP2MAPTMAPK1TDP1 | |
| SCHEMBL132403 | 0.84 | LIPE (1.00) | LIPEENPP2MAPTMAPK1TDP1 | |
| SCHEMBL27403574 | 0.82 | LIPE (0.75) | LIPEENPP2MAPTMAPK1TDP1 | |
| SCHEMBL22703367 | 0.82 | LIPE (0.75) | LIPEENPP2MAPTMAPK1TDP1 | |
| SCHEMBL3298962 | 0.81 | LIPE (0.52) | LIPEENPP2MAPTMAPK1TDP1 | |
| SCHEMBL4459609 | 0.80 | LIPE (0.48) | LIPEENPP2MAPTMAPK1TDP1 | |
| SCHEMBL9893416 | 0.80 | LIPE (0.77) | LIPEENPP2MAPTMAPK1TDP1 | |
| SCHEMBL30631479 | 0.80 | LIPE (0.77) | LIPEENPP2MAPTMAPK1TDP1 | |
| SCHEMBL1064785 | 0.80 | L3MBTL1 (0.43) | LIPEENPP2MAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133140-B2 | Cycloalkylamne derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2341044-B1 | CYCLOALKYLAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2014-02-26 | — | — | EP | disclosed |
| US-20120295943-A9 | CYCLOALKYLAMINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-22 | — | — | US | disclosed |
| US-20120122941-A1 | CYCLOALKYLAMINE DERIVATIVES | MARUMOTO SHINJI (JP) | 2012-05-17 | — | — | US | disclosed |
| EP-2341044-A1 | CYCLOALKYLAMINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-07-06 | — | — | EP | disclosed |
| EP-1781660-A1 | IMIDAZOPYRAZINE AS TYROSINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006012422-A1 | IMIDAZOPYRAZINE AS TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295943-A9 | CYCLOALKYLAMINE DERIVATIVES | CASR, CALCR, CALCRL | LIPE 971/4885ENPP2 322/4885MAPT 4507/4885 |
| US-20120122941-A1 | CYCLOALKYLAMINE DERIVATIVES | CASR, CALCR, CALCRL | LIPE 971/4885ENPP2 322/4885MAPT 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.